全球女性生殖器切割/残割的患病率:基于国家、地区、机构和学校研究的系统综述与Meta分析
该系统综述与Meta分析检索2009年至2022年3月24日的多个数据库,纳入163项研究,其中30项(来自30个国家的406,068名女性和25个国家的296,267名女孩)进入Meta分析。15至49岁女性FGM/C合并患病率为36.9%(95%CI:19.6%至58.3%),0至14岁女孩为8.27%(95%CI:3.7%至17.3%);索马里女性患病率最高(99.2%),马里女孩最高(72.7%),26个国家重复调查显示女性和女孩FGM/C均下降。
要点
- 15至49岁女性FGM/C合并患病率为36.9%(95%CI:19.6%至58.3%)
- 0至14岁女孩FGM/C合并患病率为8.27%(95%CI:3.7%至17.3%)
- 索马里女性患病率最高(99.2%),马里女孩最高(72.7%)
核心结论
- 各国FGM/C患病率差异大,许多国家患病率似在下降,但受数据缺口等影响,估计值低于实际全球患病率,许多国家仍需政策和社区干预以实现SDG目标5.3。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、PubMed、PsycINFO、Web of Science和Embase自2009年至2022年3月24日的文献,两位研究者独立筛选、质量评价和提取数据,仅纳入具有全国代表性的研究,采用广义线性混合模型(GLMM)随机效应Meta分析合并患病率,注册号CRD42020186937。
主要发现
- 共163项研究符合入选标准,其中30项纳入Meta分析(23项来自WHO非洲区域、6项来自东地中海区域、1项来自东南亚区域)。
- 纳入分析的数据包括30个国家的406,068名女性和25个国家的296,267名女孩。
- 15至49岁女性FGM/C合并患病率为36.9%(95%CI:19.6%至58.3%;预测区间PI:0.4%至99.0%),0至14岁女孩为8.27%(95%CI:3.7%至17.3%;PI:0.1%至89.3%)。
- 据此估计共有84,650,032名女性(95%CI:45,009,041至133,834,224)和13,734,845名女孩(95%CI:6,211,405至28,731,901)遭受FGM/C。
- 索马里女性FGM/C患病率最高(99.2%),马里女孩最高(72.7%);女性中最常见类型为「切除 flesh」(I型或II型,19个国家),女孩中最常见为「未缝合封闭」(I、II或IV型)和「切除 flesh」(I型或II型),各在8个国家。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究的主要方法学局限性是估计值基于已发表的可用数据,可能无法反映FGM/C的实际全球患病率。
- 由于数据缺口、分母不可比和调查不可用,该患病率估计值低于FGM/C的实际全球患病率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Female genital mutilation/cutting (FGM/C) is a nonmedical procedure entailing the modification of the external female genitalia. A description of the prevalence and distribution of FGM/C allows the tracking of progress toward ending FGM/C by 2030 (Sustainable Development Goal (SDG): target 5.3). This systematic review aimed to examine FGM/C prevalence and types, by World Health Organization (WHO) region and country. METHODS AND FINDINGS: A systematic search using Medical Subject Headings (MeSH) and keywords from 2009 to March 24, 2022 was undertaken in MEDLINE, PubMED, PsycINFO, Web of Science, and Embase to identify studies presenting FGM/C prevalence. Abstract and full-text screening, quality assessment, and data extraction were undertaken by 2 reviewers. Only nationally representative studies were included in the meta-analysis. Pooled FGM/C prevalence was estimated by random-effects meta-analysis using generalized linear mixed models (GLMMs). FGM/C prevalence with 95% confidence intervals (CIs), prediction intervals (PIs), and FGM/C type were presented separately by women aged 15 to 49 years and girls aged 0 to 14 years. A total of 163 studies met the inclusion criteria and 30 were included in the meta-analysis, of which 23 were from the WHO African Region (AFR), 6 from the Eastern Mediterranean Region (EMR), and 1 from the South East Asian Region (SEAR). These studies included data from 406,068 women across 30 countries and 296,267 girls across 25 countries; the pooled prevalence estimate of FGM/C among women aged 15 to 49 years was 36.9% (95% CI: 19.6% to 58.3%; PI: 0.4% to 99.0%), and 8.27% (95% CI: 3.7% to 17.3%; PI: 0.1% to 89.3%) among girls aged 0 to 14 years. Among included countries, this gave a total estimated prevalence of 84,650,032 women (95% CI: 45,009,041 to 133,834,224) and 13,734,845 girls with FGM/C (95% CI: 6,211,405 to 28,731,901). Somalia had the highest FGM/C prevalence among women (99.2%), and Mali had the highest among girls (72.7%). The most common type of FGM/C among women was "flesh removed" (Type I or II) in 19 countries. Among girls, "not sewn closed" (Type I, II, or IV) and "flesh removed" (Type I or II) were the most common types in 8 countries, respectively. Among repeated nationally representative studies, FGM/C decreased for both women and girls in 26 countries. The main limitation of the study methodology is that estimates were based on available published data, which may not reflect the actual global prevalence of FGM/C. CONCLUSIONS: In this study, we observed large variation in FGM/C prevalence between countries, and the prevalence appears to be declining in many countries, which is encouraging as it minimizes physical and physiological harm for a future generation of women. This prevalence estimate is lower than the actual global prevalence of FGM/C due to data gaps, noncomparable denominators, and unavailable surveys. Yet, considerable policy and community-level interventions are required in many countries to meet the SDG target 5.3. TRIAL REGISTRATION: Registration: CRD42020186937.
引用
- Farouki L, El-Dirani Z, Abdulrahim S, et al. The global prevalence of female genital mutilation/cutting: A systematic review and meta-analysis of national, regional, facility, and school-based studies. PLoS Med. 2022. PMID: 36048881. doi:10.1371/journal.pmed.1004061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。